Breaking News

Flagship Pioneering Enters Agreements Under Strategic Pfizer Pact

Will leverage Ampersand’s AND Platform and Montai’s CONECTA AI platform to identify potential obesity and lung cancer targets.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Flagship Pioneering, a bioplatform company, entered agreements with Ampersand Biomedicines and Montai Therapeutics to identify targeted molecules that could be further developed as treatments for obesity and non-small cell lung cancer (NSCLC). These agreements represent the most recent collaborations initiated under Flagship’s strategic partnership with Pfizer for the discovery and development of new targeted therapies.   The agreements with Ampersand Biomedicines and Montai Therapeutics follo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters